8-K: Precision BioSciences Implements 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

Precision BioSciences has executed a 1-for-30 reverse stock split of its common stock, effective February 13, 2024, to comply with Nasdaq's minimum bid price requirement.

Summary

• Precision BioSciences enacted a 1-for-30 reverse stock split of its common stock on February 13, 2024.
• This action was approved by stockholders at a special meeting on January 18, 2024, and subsequently by the Board of Directors on February 6, 2024.
• The reverse stock split became effective at 5:00 p.m. Eastern Time on February 13, 2024.
• Every 30 shares of existing common stock were converted into one new share.
• Fractional shares will not be issued; instead, shareholders will receive a cash payment based on the closing price on February 13, 2024.
• The stock will begin trading on a split-adjusted basis on February 14, 2024, under the existing symbol DTIL.
• The reverse stock split does not change the total number of authorized shares or the par value of the common stock.

Sentiment

Score: 5

Explanation: The document describes a necessary but not inherently positive action. The reverse stock split is a measure to avoid delisting, which is a negative situation, but the company is taking steps to address it. The sentiment is neutral to slightly negative.

Positives

• The reverse stock split is a proactive measure to maintain the company's listing on the Nasdaq Capital Market.
• The company is providing cash payments for fractional shares, ensuring fair treatment for all shareholders.

Negatives

• The reverse stock split indicates that the company's share price was below the Nasdaq minimum bid price requirement.
• The reverse stock split reduces the number of outstanding shares, which can sometimes be perceived negatively by investors.

Risks

• The reverse stock split may not be sufficient to maintain the company's listing on the Nasdaq Capital Market if the share price does not increase.
• There is a risk that the market may react negatively to the reverse stock split, potentially further impacting the share price.
• The company's ability to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market is not guaranteed.

Future Outlook

The company's ability to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market is not guaranteed, and the reverse stock split is intended to help achieve this.

Management Comments

• The Board of Directors approved the reverse stock split at a ratio of 1-for-30 following the special meeting of stockholders.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is not unique to Precision BioSciences and is often seen in the biotechnology sector.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies, particularly in the biotech sector, to regain compliance with exchange listing requirements.
• Other companies that have recently undertaken reverse stock splits include Cassava Sciences (SAVA) and Ocugen (OCGN), both of which faced similar challenges with maintaining their share price above the minimum bid price.
• The 1-for-30 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-100 depending on the specific circumstances of the company.

Corporate Governance

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively consistent immediately after the split.
• Shareholders will receive cash payments for any fractional shares resulting from the split.
• The reverse stock split is intended to maintain the company's listing on the Nasdaq, which is important for investor confidence.

Next Steps

• The company's common stock will begin trading on a split-adjusted basis on February 14, 2024.
• Shareholders who would have received fractional shares will receive cash payments.

Key Dates

Keywords

reverse stock split, Nasdaq, DTIL, common stock, share price, listing, stockholders, equity